APP Pharmaceuticals Receives Letter Regarding Nasdaq Rule 4350

Business Wire, Dec 18, 2007

SCHAUMBURG, Ill. -- APP Pharmaceuticals, Inc. (Nasdaq:APPX), a leading manufacturer of multi-source and branded injectable pharmaceutical products, today said it received a letter from The Nasdaq Stock Market, Inc. indicating that the Company was no longer in compliance with Nasdaq's Marketplace Rule 4350(d)(2). This rule requires the Company to have an audit committee of at least two independent directors as defined by the Nasdaq Marketplace Rules. In addition, one additional non-employee director can be appointed to the audit committee under certain circumstances. In connection with the tax-free spin off of its proprietary business, the Company's audit committee members resigned to become directors of the new Abraxis BioScience. As a result, APP Pharmaceuticals currently has one independent audit committee member.

APP Pharmaceuticals will hold its annual meeting of stockholders on December 19, 2007 at which time additional board members will be elected. It is anticipated that, immediately following the annual meeting, the board will appoint two additional board members to serve on the audit committee. Following these committee appointments, the Company will again be in compliance with the Nasdaq Marketplace Rules.

About APP Pharmaceuticals

Headquartered in Schaumburg, Illinois, APP's 1,400 employees are united in their commitment to operations excellence in the ultimate effort to provide products that elevate patient care. APP has offices in Canada and manufacturing operations in Illinois, New York and Puerto Rico and is traded on the Nasdaq Global Market under the symbol APPX. For more information about APP and the products it provides, please visit www.APPpharma.com.